<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26793971</article-id><article-id pub-id-type="pmc">4722757</article-id><article-id pub-id-type="publisher-id">531</article-id><article-id pub-id-type="doi">10.1186/s12883-016-0531-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5890-9888</contrib-id><name><surname>Scherbakov</surname><given-names>Nadja</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ebner</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sandek</surname><given-names>Anja</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Meisel</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Haeusler</surname><given-names>Karl Georg</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>von Haehling</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Anker</surname><given-names>Stefan D.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Dirnagl</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Joebges</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Doehner</surname><given-names>Wolfram</given-names></name><address><phone>+49 30 450 553507</phone><email>wolfram.doehner@charite.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Center for Stroke Research Berlin CSB, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Berlin, Germany </aff><aff id="Aff2"><label/>German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany </aff><aff id="Aff3"><label/>Innovative Clinical Trials, Department of Cardiology and Pneumology, University MedicineG&#x000f6;ttingen (UMG), G&#x000f6;ttingen, Germany </aff><aff id="Aff4"><label/>Department of Neurology, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Berlin, Germany </aff><aff id="Aff5"><label/>Department of Neurology, Brandenburgklinik Bernau, Bernau, Germany </aff><aff id="Aff6"><label/>Department of Cardiology, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>10</elocation-id><history><date date-type="received"><day>24</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Scherbakov et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Patients with stroke are at a high risk for long-term handicap and disability. In the first weeks after stroke muscle wasting is observed frequently. Early post-stroke rehabilitation programs are directed to improve functional independence and physical performance. Supplementation with essential amino acids (EAAs) might prevent muscle wasting and improve rehabilitation outcome by augmenting muscle mass and muscle strength. We aim to examine this in a double blinded, randomized placebo-controlled clinical trial.</p></sec><sec><title>Methods</title><p>Patients with ischemic or haemorrhagic stroke will be enrolled at begin of the early post-stroke rehabilitation in a parallel group interventional trial. Oral supplementation of EAAs or placebo will be given for 12&#x000a0;weeks in a double blinded manner. Physical and functional performance will be assessed by exercise testing before supplementation of EAAs as well as at discharge from the in-patient rehabilitation, at 12&#x000a0;weeks and 1&#x000a0;year afterwards.</p></sec><sec><title>Discussion</title><p>This is the first randomized double-blinded placebo-controlled clinical study aiming to assess the effect of the EAAs supplementation on muscle strength, muscle function and physical performance in stroke patients during early post-stroke rehabilitation. Supplementation of EAAs could prevent muscle mass wasting and improve functional independence after stroke.</p></sec><sec><title>Trial registration</title><p>The study is registered at the German registry for clinical trials as well as at World Health Organization (WHO; number <ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de/drks_web/setLocale_EN.do">DRKS00005577</ext-link>).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Double blinded randomized study</kwd><kwd>Post-stroke rehabilitation</kwd><kwd>Skeletal muscle wasting</kwd><kwd>Physical performance</kwd><kwd>Essential amino acids</kwd></kwd-group><funding-group><award-group><funding-source><institution>German Federal Ministry of Education and Research (BMBF) </institution></funding-source><award-id>01EO1301</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Long-term disability and functional dependency are the main complications after stroke. Impaired skeletal muscle innervation due to damage results in the degeneration of motor units, paresis, and immobility accompanied by skeletal muscle atrophy [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Notably, loss of muscle mass and muscle function, defined as sarcopenia, have been originally described as a phenomenon of aging [<xref ref-type="bibr" rid="CR5">5</xref>]. However, muscle wasting observed in stroke patients is a disease-related phenomenon and the term &#x02018;stroke-related sarcopenia&#x02019; has been suggested [<xref ref-type="bibr" rid="CR1">1</xref>]. The aetiology of sarcopenia is multifactorial [<xref ref-type="bibr" rid="CR6">6</xref>]. This is also true for stroke-depended sarcopenia. Several pathophysiological mechanisms including metabolic imbalance, inactivity, malnutrition, and inflammation may contribute to the reduction of muscle mass after stroke [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Stroke-related muscle wasting is accompanied by body weight loss, neuro-hormonal activation, and a systemic shift towards catabolic over-activation [<xref ref-type="bibr" rid="CR8">8</xref>]. In addition, activation of catabolic pathways in the skeletal muscle of the paretic and non-paretic limbs has been observed in experimental stroke [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Early rehabilitation has a great impact on the functional recovery after stroke. A previous study showed that 80&#x000a0;% of the patients achieve best functional recovery within 6&#x000a0;weeks after stroke, and after 12.5&#x000a0;weeks 95&#x000a0;% of all stroke patients completed their functional recovery [<xref ref-type="bibr" rid="CR10">10</xref>]. However, one year after stroke more than 30&#x000a0;% of the patients remained functionally dependent [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Skeletal muscles play a central role in post-stroke rehabilitation. The goal of rehabilitation is to restore functional muscle capacity and to prevent long-term disability. Therefore, prevention of muscle wasting, increasing muscle strength, reactive development of novel neuromuscular junctions, and stabilisation of the catabolic-anabolic imbalance are primary aims of post-stroke rehabilitation.</p><p>Nutritional intervention may contribute to the improvement of muscle bulk and functional capacity in the early post-stroke rehabilitation. Thus, a beneficial effect of dietary supplementation of essential amino acids (EAAs) has been shown for an improvement of skeletal muscle mass and function in the elderly [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Availability of EAAs is regarded as a limiting step in the synthesis of new muscle proteins [<xref ref-type="bibr" rid="CR14">14</xref>]. Previously it has been shown that supplementation of EAAs in the elderly was responsible for amino acid-induced stimulation of muscle protein anabolism [<xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, an individually adjusted rehabilitation program that includes physical, functional and neuropsychological training as well as dietary supplementation of the EAA might provide the best rehabilitation outcome. Thus, in the present clinical trial the following hypotheses will be tested:<list list-type="bullet"><list-item><p>Oral uptake of EAAs restores skeletal muscle function and physical performance;</p></list-item><list-item><p>Oral uptake of EAAs contributes to physical independence and enhances the effectiveness of post-stroke rehabilitation;</p></list-item><list-item><p>Availability of EAAs reduces muscle wasting after stroke.</p></list-item></list></p><p>We aim to demonstrate that nutritional supplementation with biologically limited available EAAs (l-leucine, l-lysine, l-isoleucine, l-valine, l-threonine, l-cystine, l-histidin, l-phenylalanine, l-methionine, l-tyrosin, and l-tryptophane), in synergy with individually adjusted physical training prevent muscle wasting after stroke and improve the effect of post-stroke early rehabilitation.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>The &#x0201c;Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation (AMINO-Stroke)&#x0201d; study is a randomized double-blinded placebo controlled interventional clinical trial. The study is planed as a monocentric trial within the interdisciplinary trial programme of the Center for Stroke Research Berlin (CSB) and is funded by the German Federal Ministry of Education and Research (BMBF; grant number CSB 01EO1301). The study has been approved by the Brandenburg Ethics Committee for the recruiting site (S13(a)/2013) and is conducted in accordance with the Declaration of Helsinki. The study is registered at the German registry for clinical trials as well as at World Health Organization (WHO; number DRKS00005577).</p></sec><sec id="Sec4"><title>Patient eligibility</title><p>Patients admitted to the rehabilitation centre Brandenburg Klinik, Bernau, Germany within 8&#x000a0;weeks after ischemic or haemorrhagic stroke will be screened for the eligibility. Patients of both genders, aged 45&#x000a0;years or older will be informed about the study. After obtaining of written informed consent from the patients they will be randomized 1:1 to intervention and control group by a web-based online randomization procedure provided by the Pharmacy at the Charit&#x000e9;. For inclusion and exclusion criteria see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria of the AMINO-Stroke</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Inclusion criteria:</td></tr><tr><td>&#x02022; Patient &#x0003e;45&#x000a0;years</td></tr><tr><td>&#x02022; Patients with ischemic or haemorrhagic stroke within 8&#x000a0;weeks to enrolment</td></tr><tr><td>&#x02022; Brain magnet resonance imaging or computer tomography demonstrating stroke</td></tr><tr><td>&#x02022; Motoric disability of an upper and /or lower limb (Rivermead Motor Assessment Gross Function&#x02009;&#x0003e;&#x02009;1 and &#x0003c;11)</td></tr><tr><td>&#x02022; Signed informed consent</td></tr><tr><td>Exclusion criteria:</td></tr><tr><td>&#x02022; Clinically significant findings on physical examination or presence of clinically significant disease that would interfere with study evaluation in the opinion of the treating physicians</td></tr><tr><td>&#x02022; Participation in another clinical trial investigating a nutritional product</td></tr><tr><td>&#x02022; History of intolerance or allergic response to similar nutritional products or known hypersensitivity to essential amino acids</td></tr><tr><td>&#x02022; Clinical sighs and symptoms of infection requiring antibiotic therapy at the time of enrolment that prevent completion of trial-related assessments as judged by the investigator</td></tr><tr><td>&#x02022; Transaminases (AST or ALT)&#x02009;&#x0003e;&#x02009;3 times the upper limit of normal (ULN)</td></tr><tr><td>&#x02022; Severe renal dysfunction or nephrotic syndrome</td></tr><tr><td>&#x02022; Acquired immunodeficiency syndrome, HIV or Hepatitis C infection</td></tr><tr><td>&#x02022; Current therapy with anabolic steroids or appetite stimulants</td></tr><tr><td>&#x02022; Current immunosuppressive therapy, heart transplantation, or renal dialysis</td></tr><tr><td>&#x02022; Life expectancy&#x02009;&#x0003c;&#x02009;6&#x000a0;months</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Planned clinical follow-up visits</title><p>In order to evaluate an effect of the EAAs on muscle function, baseline functional assessment program will be performed at admission, followed by follow-up assessment at discharge from the in-patient rehabilitation (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). All patients included into the study will receive 12&#x000a0;weeks either the EAAs (4 gram, 3 times a day) or placebo dissolved in a glass of water as a drinking solution.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Functional assessment at baseline and during follow-up</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Extended functional assessment at baseline and at 4&#x000a0;weeks follow-up</td></tr><tr><td>&#x02022; Activity of daily living (modified Rankin scale, Barthel Index)</td></tr><tr><td>&#x02022; Functional assessment scales and physical performance (Rivermead Motor Assessment Gross Function, Fugl-Meyer Scale, Functional ambulatory capacity)</td></tr><tr><td>&#x02022; Muscle functional assessment (SPPBT, hand grip, pinch grip)</td></tr><tr><td>&#x02022; Quality of life and nutritional status (EQ-5D, PGA)</td></tr><tr><td>&#x02022; Blood and biomarker bank: metabolic /immunologic profile</td></tr><tr><td>&#x02022; 24&#x000a0;h Holter electrocardiogram (ECG)</td></tr><tr><td>&#x02022; Body composition by bioelectrical impendance analysis (BIA)</td></tr><tr><td>&#x02022; Urine status</td></tr><tr><td>Functional assessment at 3 and 6&#x000a0;months follow-up</td></tr><tr><td>&#x02022; Activity of daily living (mRS, Barthel index)</td></tr><tr><td>&#x02022; Muscle functional assessment (SPPBT, hand grip, pinch grip)</td></tr><tr><td>&#x02022; Quality of life and nutritional status (EQ-5D, PGA)</td></tr><tr><td>&#x02022; Blood and biomarker bank: metabolic/immunologic profile</td></tr><tr><td>&#x02022; 24&#x000a0;h Holter ECG</td></tr><tr><td>&#x02022; Body composition by bioelectrical impedance analysis (BIA)</td></tr><tr><td>&#x02022; Urine status</td></tr></tbody></table></table-wrap></p><p>Two weeks after the enrolment a study nurse visit for evaluation of compliance of the EEAs supplementation and tolerance to the compound is planned. After discharge from the in-patient rehabilitation, two follow-up visits at 3 and at 12&#x000a0;months are planned. Patients will be tested for functional performance and physical independence during a 1-day ambulatory visit. Patients, who are unable to visit the study centre will be contacted by telephone and interviewed using a standardised questionnaire. The study design is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of the AMINO-Stroke study</p></caption><graphic xlink:href="12883_2016_531_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec6"><title>Outcomes and endpoints</title><sec id="Sec7"><title>Primary outcomes</title><p>Primary outcomes will be assessed at the 4&#x000a0;week follow-up visit. Primary endpoints include:<list list-type="order"><list-item><p>Physical performance according to the Rivermead motor assessment (RMA) <italic>gross function</italic> scale;</p></list-item><list-item><p>Muscle strength in a maximum hand grip strength test.</p></list-item></list></p></sec><sec id="Sec8"><title>Secondary outcomes</title><p>Secondary endpoints include:<list list-type="order"><list-item><p>Functional outcome assessed by Barthel Index (BI);</p></list-item><list-item><p>Quality of life assessed according to EuroQoL (EQ)-5D (EQ-5D) questionnaire at 3 and 12&#x000a0;months follow up visits;</p></list-item><list-item><p>Muscle function and motor capabilities assessed by pinch grip strength test, motor assessment scale, Fugl-Meyer Score (motor functional domain), Functional ambulatory capacity and short physical performance battery test;</p></list-item><list-item><p>Changes of body composition assessed by bioelectrical impedance analysis (BIA);</p></list-item><list-item><p>Changes in insulin sensitivity;</p></list-item><list-item><p>Changes of nutritional status according to Mini Nutritional Assessment questionnaire and metabolic profile according to biochemical analyses;</p></list-item><list-item><p>Rate of post-stroke complications, stroke &#x02013;associated infections and re-hospitalization for any reason;</p></list-item><list-item><p>Safety and tolerability of EEAs supplementation.</p></list-item></list></p></sec><sec id="Sec9"><title>Physical examinations</title><p><italic>Rivermead motor assessment (RMA) gross function scale</italic> comprised a series of 13 questions, and covers a range of activities from turning over in bed to hop on affected leg five times [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. <italic>Hand grip strength</italic> [<xref ref-type="bibr" rid="CR18">18</xref>] <italic>and pinch grip tests measures</italic> muscle isometric strength. The maximum value of three measurements will be evaluated [<xref ref-type="bibr" rid="CR19">19</xref>]. <italic>Motor assessment scale (MAS)</italic> includes nine items scoring from 0 to 6, and is designed to assess eight areas of motor function, balance, and muscle tone [<xref ref-type="bibr" rid="CR20">20</xref>]. <italic>Fugl-Meyer scale</italic> is a system for the evaluation of motor function, balance, sensory qualities, and joint function in hemiplegic patients. This system applies a cumulative numerical score [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. <italic>Functional Ambulation Category (FAC)</italic> includes six categories ranging from 0 to 5 and is defined by ability of the patient to ambulate, with a lowest score 0 for &#x0201c;patient cannot ambulate&#x0201d; to 5 &#x0201c;patient can ambulate independently&#x0201d; [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec10"><title>Functional independency assessment</title><p><italic>Barthel index (BI)</italic> will be used for the assessment of functional independence. BI includes 10 basic aspects of activities related to self-care and mobility with scores of 0&#x02013;100, where the lower scores indicate greater dependency [<xref ref-type="bibr" rid="CR24">24</xref>]. <italic>Short physical performance battery test (SPPBT)</italic> includes examination of ability to stand with the feet together in the side-by-side, semi-tandem, and tandem positions, time to walk 3 or 4 meters, and time to rise from the chair and return to the seated position 5 times [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec11"><title>Nutritional status and quality of life</title><p><italic>Mini Nutritional Assessment (MNA)</italic> is a simple scale to measure nutritional status [<xref ref-type="bibr" rid="CR26">26</xref>]. A score above 24 points identifies patients with a good nutritional status, whereas a score below 17 points reveals patients with malnutrition. <italic>Subjective Global Assessment (SGA)</italic> assesses nutritional status based on features of the history and physical examination [<xref ref-type="bibr" rid="CR27">27</xref>]. <italic>EQ-5D questionnaire</italic> is an instrument for the generic measurements of health-related quality of life, comprising a Visual Analogue Scale for self-rating of general health and five domains evaluating mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [<xref ref-type="bibr" rid="CR28">28</xref>]. A score of 1 is the best possible general health status in each case; the dimensions may also be expressed as percentage of patients scoring from 1 to 3 (best to worst health status) or percentage of patients with &#x02018;any&#x02019; complaint (scoring 2 or 3 in each domain) [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec12"><title>Body composition analysis</title><p>Body composition analysis at baseline and follow-up visits will be assessed by BIA device (BodyStat QuadScan 4000, Bodystat Limited, British Isles). The BIA device measures resistance (<italic>R</italic>), reactance (<italic>Xc</italic>) and phase angle (<italic>&#x003c6;</italic>). The measurements will be performed in patients in supine position lying on a non-conducting surface with arms slightly abducted from the trunk and legs slightly separated, after resting at least for 20&#x000a0;min [<xref ref-type="bibr" rid="CR30">30</xref>]. Surface electrodes will be placed on the dorsal surface of hand and foot of the similar side. Skeletal muscle (SM) mass will be estimated according to the equation of Baumgartner at all [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec13"><title>Serum biomarker assessment</title><p>Blood samples and urine status will be assessed at admission and discharge from the inpatient rehabilitation as well as at follow up visits for routine clinical parameters, inflammatory and metabolic markers, and safety analyses (liver and kidney function).</p></sec></sec><sec id="Sec14"><title>Sample size calculation and statistical analyses</title><p>A total of 110 patients is planned to be enrolled in the study. A prospective sample size calculation has been performed based on observational data from our study centre. A sample size of 55 in each group will have 80&#x000a0;% power to detect a clinically relevant difference in Rivermead Motor Assessment Gross Function scale improvement between the groups of 1.5 points and a clinically relevant improvement of handgrip strength. The analysis of primary endpoints will use the principle of intention- to-treat. The carry-forward principle will be adopted for unavailable or missing data. Treatment effect will be assessed by unpaired comparison of both treatment arms for the change from baseline using the Student t-test. A significance level of &#x003b1;&#x02009;&#x0003c;&#x02009;0.05 will be specified to indicate statistical significance. Secondary endpoints will be analyzed using standard statistical methods. For safety endpoints Chi-squared test of Fisher&#x02019;s Exact test will be used for event rates (e.g., death, re-stroke, hospitalization, cardiovascular event)</p></sec></sec><sec id="Sec15"><title>Discussion</title><p>The present AMINO Stroke study will be the first randomized double-blinded trial investigating an effect of essential amino acids (EAAs) on skeletal muscle functional capacity, muscle mass, muscle strength and physical performance in early post-stroke rehabilitation. In addition, the effect of EAAs supplementation on stroke-related quality of life, nutritional status, activities of daily life and outcome will be evaluated.</p><p>An improvement of physical and functional performance in stroke patients is expected after participating in 4-weeks rehabilitation program [<xref ref-type="bibr" rid="CR32">32</xref>]. In the present study we expect a beneficial impact of the dietary supplementation of the EAA on skeletal muscle function and muscle mass during post-stroke rehabilitation.</p><p>The benefit of EAAs supplementation on skeletal muscle has been shown in several studies in elderly individuals. Thus, an elevated level of muscle protein synthesis was dependent on the availability of EAAs in a dose-depended manner [<xref ref-type="bibr" rid="CR33">33</xref>]. An experimental study performing in the young adults revealed an increase of leucine incorporation into the skeletal muscle proteins under administration of EEAs as a flooding dose [<xref ref-type="bibr" rid="CR34">34</xref>]. Ingestion of EAAs shortly after exercise enhanced muscle protein synthesis in older adults, indicating a combination of EAAs with exercising as a sufficient therapy for the treatment of muscle wasting [<xref ref-type="bibr" rid="CR35">35</xref>]. Another study showed an improvement of lean mass, muscle functional capacity and muscle strength after 16&#x000a0;weeks supplementation of EAAs and arginine in healthy elderly individuals [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>A reduction of the muscle mass might be directly depending on a limited availability of the EEAs and other nutrients [<xref ref-type="bibr" rid="CR14">14</xref>]. Impaired feeding which results in malnutrition is frequently observed in patients with dysphagia after stroke [<xref ref-type="bibr" rid="CR37">37</xref>]. About 50&#x000a0;% of stroke patients have feeding difficulties due to dysphagia [<xref ref-type="bibr" rid="CR38">38</xref>]. In older patients reduced nutritional status might be observed already at hospital admission with the diagnosis of acute stroke [<xref ref-type="bibr" rid="CR39">39</xref>]. Patients with lower body weight have been observed to have worse fatal and non-fatal outcome after stroke [<xref ref-type="bibr" rid="CR40">40</xref>]. While the inverse association of overweight and improved outcome has previously been termed obesity paradox [<xref ref-type="bibr" rid="CR41">41</xref>], the perception advanced towards an obesity paradigm, acknowledging the protective overweight in cardiovascular disease [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>Malnutrition and sarcopenia are often reported in the rehabilitation setting [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Therefore, we believe that supplementation of the EAAs will contribute to attenuation of muscle wasting and improve skeletal muscle recovery [<xref ref-type="bibr" rid="CR45">45</xref>]. There are a number of methods available to assess muscle mass [<xref ref-type="bibr" rid="CR46">46</xref>]. In the present study muscle mass will be estimated by using BIA that provides information to integrity of cell membrane and tissue interfaces, intracellular and extracellular fluid distribution, body fat and body lean mass [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Previously, a strong correlation between muscle mass assessed by BIA and magnetic resonance imaging has been shown [<xref ref-type="bibr" rid="CR48">48</xref>]. The prevalence of sarcopenia using BIA measurements has been repeatedly examined in elderly [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and in patients with neuromuscular or cerebrovascular disease [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Therefore we believe that BIA is an appropriate method for muscle mass assessment.</p><p>In Germany, stroke has not been selected for chronic disease management programs so far [<xref ref-type="bibr" rid="CR53">53</xref>]. Post-stroke rehabilitation is usually recommended to start immediately following hospital discharge. The so called early post-stroke rehabilitation phase includes about 4&#x000a0;weeks. Mainly, recommendations given in discharge letters from acute care hospitals are frequently focusing on medical treatments [<xref ref-type="bibr" rid="CR53">53</xref>]. At present, post-stroke management does not include monitoring of muscle mass, muscle strength and muscle function. The European stroke guidelines do not consider post-stroke muscle wasting as a relevant complication [<xref ref-type="bibr" rid="CR54">54</xref>]. However, recognition of this problem through the medical community might improve the long-term outcome after stroke.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>EEA</term><def><p>Essential amino acid</p></def></def-item><def-item><term>BI</term><def><p>Barthel Index</p></def></def-item><def-item><term>EQ-5D</term><def><p>Quality of life questionnaire</p></def></def-item><def-item><term>RMA</term><def><p>Rivermead motor assessment</p></def></def-item><def-item><term>MAS</term><def><p>Motor assessment scale</p></def></def-item><def-item><term>FAC</term><def><p>Functional ambulation category</p></def></def-item><def-item><term>SPPBT</term><def><p>Short physical performance battery test</p></def></def-item><def-item><term>MNA</term><def><p>Mini nutritional assessment</p></def></def-item><def-item><term>SGA</term><def><p>Subjective global assessment</p></def></def-item><def-item><term>BIA</term><def><p>Bioelectrical impedance analysis</p></def></def-item><def-item><term>SM</term><def><p>Skeletal muscle</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>KGH reports lecture fees and study grants by Bayer Healthcare, lecture fees and a study grant by Sanofi, lecture fees and advisory board fees from Pfizer, lecture fees from Bristol-Myers Squibb as well as advisory board fees from Edwards Lifesciences. Other authors report no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contribution</bold></p><p>WD, UD and MJ intended this analysis and designed the study. WD performed the statistical calculations. NS wrote the manuscript. NS, NE, AS, AM, KGH, SvH, SDA made substantial contributions to the study design. NE initiated the registry of the trial. All authors contributed relevant intellectual content to the manuscript and approved the final version.</p></fn></fn-group><ack><p>We thank Mrs. Anja Kresse for the valuable assistance in the preparation and documentation of this study and Dr. Francesco S. Dioguardi for providing the EAAs supplementation.</p><sec id="FPar1"><title>Funding</title><p>The Center for Stroke Research Berlin (CSB) is an integrated research and treatment centre. The AMINO Stroke Study receives funding from German Federal Ministry of Education and Research (BMBF; grant number BMBF 01EO1301).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherbakov</surname><given-names>N</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name></person-group><article-title>Sarcopenia in stroke-facts and numbers on muscle loss accounting for disability after stroke</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2011</year><volume>2</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s13539-011-0024-8</pub-id><pub-id pub-id-type="pmid">21475676</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherbakov</surname><given-names>N</given-names></name><name><surname>Sandek</surname><given-names>A</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name></person-group><article-title>Stroke-related sarcopenia: specific characteristics</article-title><source>J Am Med Dir Assoc</source><year>2015</year><volume>16</volume><fpage>272</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2014.12.007</pub-id><pub-id pub-id-type="pmid">25676847</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carin-Levy</surname><given-names>G</given-names></name><name><surname>Greig</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Hannan</surname><given-names>J</given-names></name><name><surname>Mead</surname><given-names>G</given-names></name></person-group><article-title>Longitudinal changes in muscle strength and mass after acute stroke</article-title><source>Cerebrovasc Dis</source><year>2006</year><volume>21</volume><fpage>201</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000090792</pub-id><pub-id pub-id-type="pmid">16401884</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>L</given-names></name><name><surname>Jacobsen</surname><given-names>BK</given-names></name></person-group><article-title>Changes in MM, fat mass, and bone mineral content in the legs after stroke: a 1&#x000a0;year prospective study</article-title><source>Bone</source><year>2001</year><volume>28</volume><fpage>655</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S8756-3282(01)00434-3</pub-id><pub-id pub-id-type="pmid">11425655</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>IH</given-names></name></person-group><article-title>Sarcopenia: origins and clinical relevance</article-title><source>J Nutr</source><year>1997</year><volume>127</volume><fpage>990S</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">9164280</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boirie</surname><given-names>Y</given-names></name></person-group><article-title>Physiopathological mechanism of sarcopenia</article-title><source>J Nutr Health Aging</source><year>2009</year><volume>13</volume><fpage>717</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s12603-009-0203-x</pub-id><pub-id pub-id-type="pmid">19657556</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherbakov</surname><given-names>N</given-names></name><name><surname>von Haehling</surname><given-names>S</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name></person-group><article-title>Stroke induced Sarcopenia: muscle wasting and disability after stroke</article-title><source>Int J Cardiol</source><year>2013</year><volume>170</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2013.10.031</pub-id><pub-id pub-id-type="pmid">24231058</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherbakov</surname><given-names>N</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name></person-group><article-title>Body weight after stroke: lessons from the obesity paradox</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>3646</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.619163</pub-id><pub-id pub-id-type="pmid">21960580</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springer</surname><given-names>J</given-names></name><name><surname>Schust</surname><given-names>S</given-names></name><name><surname>Peske</surname><given-names>K</given-names></name><name><surname>Tschirner</surname><given-names>A</given-names></name><name><surname>Rex</surname><given-names>A</given-names></name><name><surname>Engel</surname><given-names>O</given-names></name><etal/></person-group><article-title>Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>3675</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.114.006258</pub-id><pub-id pub-id-type="pmid">25352483</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>HS</given-names></name><name><surname>Nakayama</surname><given-names>H</given-names></name><name><surname>Raaschou</surname><given-names>HO</given-names></name><name><surname>Vive-Larsen</surname><given-names>J</given-names></name><name><surname>St&#x000f8;ier</surname><given-names>M</given-names></name><name><surname>Olsen</surname><given-names>TS</given-names></name></person-group><article-title>Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study</article-title><source>Arch Phys Med Rehabil</source><year>1995</year><volume>76</volume><fpage>406</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0003-9993(95)80568-0</pub-id><pub-id pub-id-type="pmid">7741609</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamford</surname><given-names>J</given-names></name><name><surname>Sandercock</surname><given-names>P</given-names></name><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Warlow</surname><given-names>C</given-names></name></person-group><article-title>A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1990</year><volume>53</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1136/jnnp.53.1.16</pub-id><pub-id pub-id-type="pmid">2303826</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondanelli</surname><given-names>M</given-names></name><name><surname>Opizzi</surname><given-names>A</given-names></name><name><surname>Antoniello</surname><given-names>N</given-names></name><name><surname>Boschi</surname><given-names>F</given-names></name><name><surname>Iadarola</surname><given-names>P</given-names></name><name><surname>Pasini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of essential amino acid supplementation on quality of life, amino acid profile and strength in institutionalized elderly patients</article-title><source>Clin Nutr</source><year>2011</year><volume>30</volume><fpage>571</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2011.04.005</pub-id><pub-id pub-id-type="pmid">21636183</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>JM</given-names></name><name><surname>Verlaan</surname><given-names>S</given-names></name><name><surname>Bautmans</surname><given-names>I</given-names></name><name><surname>Brandt</surname><given-names>K</given-names></name><name><surname>Donini</surname><given-names>LM</given-names></name><name><surname>Maggio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial</article-title><source>J Am Med Dir Assoc</source><year>2015</year><volume>16</volume><fpage>740</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2015.05.021</pub-id><pub-id pub-id-type="pmid">26170041</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dioguardi</surname><given-names>FS</given-names></name></person-group><article-title>Clinical use of amino acids as dietary supplement: pros and cons</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2011</year><volume>2</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s13539-011-0032-8</pub-id><pub-id pub-id-type="pmid">21766052</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpi</surname><given-names>E</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Sheffield-Moore</surname><given-names>M</given-names></name><name><surname>Mittendorfer</surname><given-names>B</given-names></name><name><surname>Wolfe</surname><given-names>RR</given-names></name></person-group><article-title>Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>78</volume><fpage>250</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12885705</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>N</given-names></name><name><surname>Leadbitter</surname><given-names>D</given-names></name></person-group><article-title>Assessment of motor function in stroke patients</article-title><source>Physiotherapy</source><year>1979</year><volume>65</volume><fpage>48</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">441189</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collen</surname><given-names>FM</given-names></name><name><surname>Wade</surname><given-names>DT</given-names></name><name><surname>Robb</surname><given-names>GF</given-names></name><name><surname>Bradshaw</surname><given-names>CM</given-names></name></person-group><article-title>The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment</article-title><source>Int Disabil Stud</source><year>1991</year><volume>13</volume><fpage>50</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3109/03790799109166684</pub-id><pub-id pub-id-type="pmid">1836787</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohannon</surname><given-names>RW</given-names></name></person-group><article-title>Adequacy of hand-grip dynamometer for characterizing upper limb strength after stroke</article-title><source>Isokinet Exerc Sci</source><year>2004</year><volume>12</volume><fpage>263</fpage><lpage>5</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiowetz</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name><name><surname>Volland</surname><given-names>G</given-names></name><name><surname>Kashman</surname><given-names>N</given-names></name></person-group><article-title>Reliability and validity of grip and pinch strength evaluations</article-title><source>J Hand Surg [Am]</source><year>1984</year><volume>9</volume><fpage>222</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0363-5023(84)80146-X</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>JH</given-names></name><name><surname>Shepherd</surname><given-names>RB</given-names></name><name><surname>Nordholm</surname><given-names>L</given-names></name><name><surname>Lynne</surname><given-names>D</given-names></name></person-group><article-title>Investigation of a new motor assessment scale for stroke patients</article-title><source>Phys Ther</source><year>1985</year><volume>65</volume><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">3969398</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fugl-Meyer</surname><given-names>AR</given-names></name><name><surname>J&#x000e4;&#x000e4;sk&#x000f6;</surname><given-names>L</given-names></name><name><surname>Leyman</surname><given-names>I</given-names></name><name><surname>Olsson</surname><given-names>S</given-names></name><name><surname>Steglind</surname><given-names>S</given-names></name></person-group><article-title>The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance</article-title><source>Scand J Rehabil Med</source><year>1975</year><volume>7</volume><fpage>13</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1135616</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>KJ</given-names></name><name><surname>Tilson</surname><given-names>JK</given-names></name><name><surname>Cen</surname><given-names>SY</given-names></name><name><surname>Rose</surname><given-names>DK</given-names></name><name><surname>Hershberg</surname><given-names>J</given-names></name><name><surname>Correa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fugl-Meyer assessment of sensorimotor function after stroke: standardized training procedure for clinical practice and clinical trials</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>427</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.110.592766</pub-id><pub-id pub-id-type="pmid">21164120</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holden</surname><given-names>MK</given-names></name><name><surname>Gill</surname><given-names>KM</given-names></name><name><surname>Magliozzi</surname><given-names>MR</given-names></name><name><surname>Nathan</surname><given-names>J</given-names></name><name><surname>Piehl-Baker</surname><given-names>L</given-names></name></person-group><article-title>Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness</article-title><source>Phys Ther</source><year>1984</year><volume>64</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">6691052</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasner</surname><given-names>SE</given-names></name></person-group><article-title>Clinical interpretation and use of stroke scales</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><fpage>603</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70495-1</pub-id><pub-id pub-id-type="pmid">16781990</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Berkman</surname><given-names>LF</given-names></name><name><surname>Blazer</surname><given-names>DG</given-names></name><etal/></person-group><article-title>A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission</article-title><source>J Gerontol</source><year>1994</year><volume>49</volume><fpage>M85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/geronj/49.2.M85</pub-id><pub-id pub-id-type="pmid">8126356</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Villars</surname><given-names>H</given-names></name><name><surname>Abellan</surname><given-names>G</given-names></name><name><surname>Soto</surname><given-names>ME</given-names></name><name><surname>Rolland</surname><given-names>Y</given-names></name><name><surname>Guigoz</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Overview of the MNA--Its history and challenges</article-title><source>J Nutr Health Aging</source><year>2006</year><volume>10</volume><fpage>456</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17183418</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detsky</surname><given-names>AS</given-names></name><name><surname>McLaughlin</surname><given-names>JR</given-names></name><name><surname>Baker</surname><given-names>JP</given-names></name><name><surname>Johnston</surname><given-names>N</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Mendelson</surname><given-names>RA</given-names></name><etal/></person-group><article-title>What is subjective global assessment of nutritional status?</article-title><source>JPEN J Parenter Enteral Nutr</source><year>1987</year><volume>11</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1177/014860718701100108</pub-id><pub-id pub-id-type="pmid">3820522</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>NJ</given-names></name><name><surname>Krabbe</surname><given-names>PF</given-names></name></person-group><article-title>The development of new research methods for the valuation of EQ-5D-5&#x000a0;L</article-title><source>Eur J Health Econ</source><year>2013</year><volume>14</volume><fpage>S1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1007/s10198-013-0502-3</pub-id><pub-id pub-id-type="pmid">23900659</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comin-Colet</surname><given-names>J</given-names></name><name><surname>Lainscak</surname><given-names>M</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Filippatos</surname><given-names>GS</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name><name><surname>L&#x000fc;scher</surname><given-names>TF</given-names></name><etal/></person-group><article-title>The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>30</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr504</pub-id><pub-id pub-id-type="pmid">22297124</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukaski</surname><given-names>HC</given-names></name><name><surname>Johnson</surname><given-names>PE</given-names></name><name><surname>Bolonchuk</surname><given-names>WW</given-names></name><name><surname>Lykken</surname><given-names>GI</given-names></name></person-group><article-title>Assessment of fat-free mass using bioelectrical impedance measurements of the human body</article-title><source>Am J Clin Nutr</source><year>1985</year><volume>41</volume><fpage>810</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3984933</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgartner</surname><given-names>RN</given-names></name><name><surname>Chumlea</surname><given-names>WC</given-names></name><name><surname>Roche</surname><given-names>AF</given-names></name></person-group><article-title>Bioelectric impedance phase angle and body composition</article-title><source>Am J Clin Nutr</source><year>1988</year><volume>48</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">3389323</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Scherbakov N, Knops M, Ebner N, Valentova M, Sandek A, Grittner U, et al. Evaluation of C-terminal Agrin Fragment as a marker ofmuscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle. doi:10.1002/jcsm.12068</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuthbertson</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Babraj</surname><given-names>J</given-names></name><name><surname>Leese</surname><given-names>G</given-names></name><name><surname>Waddell</surname><given-names>T</given-names></name><name><surname>Atherton</surname><given-names>P</given-names></name><etal/></person-group><article-title>Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>422</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15596483</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Reynolds</surname><given-names>N</given-names></name><name><surname>Downie</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Rennie</surname><given-names>MJ</given-names></name></person-group><article-title>Effects of flooding amino acids on incorporation of labeled amino acids into human muscle protein</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>E73</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9688876</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>DK</given-names></name><name><surname>Dickinson</surname><given-names>JM</given-names></name><name><surname>Timmerman</surname><given-names>KL</given-names></name><name><surname>Drummond</surname><given-names>MJ</given-names></name><name><surname>Reidy</surname><given-names>PT</given-names></name><name><surname>Fry</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Exercise, amino acids, and aging in the control of human muscle protein synthesis</article-title><source>Med Sci Sports Exerc</source><year>2011</year><volume>43</volume><fpage>2249</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1249/MSS.0b013e318223b037</pub-id><pub-id pub-id-type="pmid">21606874</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;rsheim</surname><given-names>E</given-names></name><name><surname>Bui</surname><given-names>QU</given-names></name><name><surname>Tissier</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Wolfe</surname><given-names>RR</given-names></name></person-group><article-title>Effect of amino acid supplementation on MM, strength and physical function in elderly</article-title><source>Clin Nutr</source><year>2008</year><volume>27</volume><fpage>189</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2008.01.001</pub-id><pub-id pub-id-type="pmid">18294740</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>NC</given-names></name><name><surname>Martin</surname><given-names>RE</given-names></name><name><surname>Salter</surname><given-names>KL</given-names></name><name><surname>Teasell</surname><given-names>RW</given-names></name></person-group><article-title>A review of the relationship between dysphagia and malnutrition following stroke</article-title><source>J Rehabil Med</source><year>2009</year><volume>41</volume><fpage>707</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.2340/16501977-0415</pub-id><pub-id pub-id-type="pmid">19774302</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geeganage</surname><given-names>C</given-names></name><name><surname>Beavan</surname><given-names>J</given-names></name><name><surname>Ellender</surname><given-names>S</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name></person-group><article-title>Interventions for dysphagia and nutritional support in acute and subacute stroke</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>10</volume><fpage>CD000323</fpage><pub-id pub-id-type="pmid">23076886</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirlich</surname><given-names>M</given-names></name><name><surname>Sch&#x000fc;tz</surname><given-names>T</given-names></name><name><surname>Norman</surname><given-names>K</given-names></name><name><surname>Gastell</surname><given-names>S</given-names></name><name><surname>L&#x000fc;bke</surname><given-names>HJ</given-names></name><name><surname>Bischoff</surname><given-names>SC</given-names></name><etal/></person-group><article-title>The German hospital malnutrition study</article-title><source>Clin Nutr</source><year>2006</year><volume>25</volume><fpage>563</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2006.03.005</pub-id><pub-id pub-id-type="pmid">16698132</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Schenkel</surname><given-names>J</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Springer</surname><given-names>J</given-names></name><name><surname>Audebert</surname><given-names>HJ</given-names></name></person-group><article-title>Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>268</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs340</pub-id><pub-id pub-id-type="pmid">23076781</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainscak</surname><given-names>M</given-names></name><name><surname>von Haehling</surname><given-names>S</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name></person-group><article-title>The obesity paradox in chronic disease: facts and numbers</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2012</year><volume>3</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s13539-012-0059-5</pub-id><pub-id pub-id-type="pmid">22450395</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Doehner W, von Haehling S, Anker SD. Protective overweight in cardiovascular disease: moving from &#x02018;paradox&#x02019; to &#x02018;paradigm&#x02019;. Eur Heart J. 2015. (pubmed ahead of print).</mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>H</given-names></name><name><surname>Sakuma</surname><given-names>K</given-names></name></person-group><article-title>Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2014</year><volume>5</volume><fpage>269</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s13539-014-0162-x</pub-id><pub-id pub-id-type="pmid">25223471</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>JP</given-names></name></person-group><article-title>Sarcopenia: there is a need for some steps forward</article-title><source>J Am Med Dir Assoc</source><year>2014</year><volume>15</volume><fpage>379</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2014.03.016</pub-id><pub-id pub-id-type="pmid">24794828</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malafarina</surname><given-names>V</given-names></name><name><surname>Uriz-Otano</surname><given-names>F</given-names></name><name><surname>Iniesta</surname><given-names>R</given-names></name><name><surname>Gil-Guerrero</surname><given-names>L</given-names></name></person-group><article-title>Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review</article-title><source>J Am Med Dir Assoc</source><year>2013</year><volume>14</volume><fpage>10</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2012.08.001</pub-id><pub-id pub-id-type="pmid">22980996</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heymsfield</surname><given-names>SB</given-names></name><name><surname>Adamek</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>MC</given-names></name><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>DM</given-names></name></person-group><article-title>Assessing skeletal muscle mass: historical overview and state of the art</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2014</year><volume>5</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s13539-014-0130-5</pub-id><pub-id pub-id-type="pmid">24532493</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>K</given-names></name><name><surname>Wirth</surname><given-names>R</given-names></name><name><surname>Neubauer</surname><given-names>M</given-names></name><name><surname>Eckardt</surname><given-names>R</given-names></name><name><surname>Stob&#x000e4;us</surname><given-names>N</given-names></name></person-group><article-title>The bioimpedance phase angle predicts low muscle strength, impaired quality of life, and increased mortality in old patients with cancer</article-title><source>J Am Med Dir Assoc</source><year>2015</year><volume>16</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.1016/j.jamda.2014.10.024</pub-id><pub-id pub-id-type="pmid">25499428</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Heymsfield</surname><given-names>SB</given-names></name><name><surname>Baumgartner</surname><given-names>RN</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Estimation of skeletal MM by bioelectrical impedance analysis</article-title><source>J Appl Physiol (1985)</source><year>2000</year><volume>89</volume><fpage>465</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10926627</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Heymsfield</surname><given-names>SB</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Low relative skeletal MM (sarcopenia) in older persons is associated with functional impairment and physical disability</article-title><source>J Am Geriatr Soc</source><year>2002</year><volume>50</volume><fpage>889</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1046/j.1532-5415.2002.50216.x</pub-id><pub-id pub-id-type="pmid">12028177</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>D</given-names></name><name><surname>Vaes</surname><given-names>B</given-names></name><name><surname>Mathe&#x000ef;</surname><given-names>C</given-names></name><name><surname>Swine</surname><given-names>C</given-names></name><name><surname>Degryse</surname><given-names>JM</given-names></name></person-group><article-title>The prevalence of sarcopenia in very old individuals according to the European consensus definition: insights from the BELFRAIL study</article-title><source>Age Ageing</source><year>2013</year><volume>42</volume><fpage>727</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/ageing/aft128</pub-id><pub-id pub-id-type="pmid">24014657</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutkove</surname><given-names>SB</given-names></name><name><surname>Aaron</surname><given-names>R</given-names></name><name><surname>Shiffman</surname><given-names>CA</given-names></name></person-group><article-title>Localized bioimpedance analysis in the evaluation of neuromuscular disease</article-title><source>Muscle Nerve</source><year>2002</year><volume>25</volume><fpage>390</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/mus.10048</pub-id><pub-id pub-id-type="pmid">11870716</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotillo</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez-Jurado</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>E</given-names></name><name><surname>Mataix</surname><given-names>J</given-names></name><name><surname>Llopis</surname><given-names>J</given-names></name></person-group><article-title>Body composition assessed by anthropometry and bioelectric impedance analysis in older persons recovering from cerebrovascular accident</article-title><source>Int J Vitam Nutr Res</source><year>2003</year><volume>73</volume><fpage>32</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1024/0300-9831.73.1.32</pub-id><pub-id pub-id-type="pmid">12690909</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leistner</surname><given-names>S</given-names></name><name><surname>Michelson</surname><given-names>G</given-names></name><name><surname>Laumeier</surname><given-names>I</given-names></name><name><surname>Ahmadi</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>M</given-names></name><name><surname>Nieweler</surname><given-names>G</given-names></name><etal/></person-group><article-title>Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial</article-title><source>BMC Neurol</source><year>2013</year><volume>13</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-13-11</pub-id><pub-id pub-id-type="pmid">23347503</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Stroke Organisation (ESO) Executive Committee</collab><collab>ESO Writing Committee</collab></person-group><article-title>Guidelines for management of ischaemic stroke and transient ischaemic attack 2008</article-title><source>Cerebrovasc Dis</source><year>2008</year><volume>25</volume><issue>5</issue><fpage>457</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1159/000131083</pub-id><pub-id pub-id-type="pmid">18477843</pub-id></element-citation></ref></ref-list></back></article>